Live on Bloomberg TV

00:00ANOTHER EVENT HAPPENING OUT WITH RIGHT NOW, THE ANNUAL JPMORGAN HEALTH CARE CONFERENCE IN SAN FRANCISCO. TAYLOR RIGGS SAT DOWN WITH CHRISTOPH WEBER, THE PRESIDENT AND CEO OF CICADA PHARMACEUTICAL FOR EXCLUSIVE INTERVIEW. SHE ASKED HIM ABOUT THE INTEGRATION OF CICADA AND SHIRE AND SOME OF THE BIGGEST CHALLENGES HE IS FACING OUR. -- FACING ARE. > > WE STARTED QUITE A LONG TIME AGO AND WE ARE VERY WELL ADVANCED WITH INTEGRATION. WE HAVE ALREADY NOMINATED THE TOP 200 LEADER OF THE COMPANY AND THE ORGANIZATION IS ALREADY DESIGNED, THE STRATEGY IS VERY CLEAR IN FACT ON THURSDAY, TWO DAYS AFTER THE CLOSING DATE, WE HAVE OUR FIRST CONFERENCE WITH THE TOP 200 LITERS. I THINK WE ARE VERY WELL ADVANCED. TAYLOR: I WANT TO TALK ABOUT DEBT, INCREASING THE DEBT LOAD HELP ON THIS DEAL, YOU HAVE A TARGET OF A NET DEBT RATIO OF ABOUT TWO TIMES. IN A DOWNGRADE FROM MOODY ' S, S & P ON TUESDAY MORNING DOWNGRADED INTO TRIPLE B PLUS. WHAT IS YOUR STRATEGY ABOUT GETTING THAT DEBT LEVEL BACK TO AN AREA WHERE YOU ARE COMFORTABLE WITH? > > WE -- OUR COMMITMENT IS TO BE INVESTMENT-GRADE AND WE ARE INVESTMENT-GRADE. WE HAVE TO DELIVER EDGE RAPIDLY. WE WILL DO THAT BY THE CASH FLOW GENERATED BY THE COMPANY, THE COMPANY WITH A VERY HIGH MARGIN OF THE STARTING POINT OF 37, IT ' S A VERY CASH FLOW GENERATED COMPANY. WE WILL ALSO DO SOME DISPOSAL TO ACCELERATE THE LIBERATION. OUR INTENT IS TO BE BACK AT TWO TIMES THE RATE OF THREE YEARS AGO. TAYLOR: TALK ABOUT THE DIVESTITURES YOU PLAN ON MAKING TO GET BACK TO YOUR CORE ASSET IN YOUR FOCUS. > > 75% OF OUR TOTAL BUSINESS OUR CORE ASSETS. WE HAVE 25% OF OUR BUSINESS WHICH IS NON-CORE. WE WILL SELECT OF WHAT WE WILL DISPOSE. WE ALREADY IN FACT STARTED THE PROCESS IS WEAK AND WE ARE DIALOGUING WITH BUYERS. WE WANT TO DISPOSE FOR TOTAL VALUE OF AROUND $10 BILLION. TAYLOR: WHO ARE THOSE BUYERS? > > IT COULD BE PRIVATE EQUITY IS, ALL TITLE BUYERS. SOME METHODS ARE GLOBAL ASSETS, SOME ARE MORE LOCAL OR REGIONAL. IT ' S BEEN ON THE ASSETS. TAYLOR: WE ' VE SEEN A LOT OF M & A THIS YEAR, BRISTOL-MYERS SQUIBB BROUGHT -- BOUGHT CELGENE. HOW MUCH PRESSURE DO YOU FEEL IS THE CONSCIOUS NEEDS OF AROUND YOU? > > THE KEY IS TO INNOVATE AND TO BE ABLE TO DELIVER HIGHLY INNOVATIVE MISSIONS THROUGH R & D, THAT ' S OUR STRATEGY. IN THE AREAS WE HAVE SELECTED, WE SELECTED FOR THEIR OF THE AREAS ON WHICH WE WANT TO CONCENTRATE R & D, WE FEEL THAT WE ARE HIGHLY COMPETITIVE, WE HAVE THE KNOW-HOW IN THE KNOWLEDGE AND THE BEST TEAM, WE HAVE THE FINANCIAL RESOURCE. THAT IS OUR STRATEGY TO BE ABLE TO COMPETE. VONNIE: THE PRESIDENT AND CEO TO ACADIA PHARMACEUTICALS SPEAKING

No schedule data available.

Takeda Is Focused on Innovation Through R&D, CEO Says

Christophe Weber, Takeda Pharmaceutical Co. chief executive officer, discusses the company's business strategy with Bloomberg's Taylor Riggs on "Bloomberg Markets." (Source: Bloomberg)

More From Bloomberg Markets
All episodes and clips

The David Rubenstein Show
The David Rubenstein Show: Peer-to-Peer Conversations" explores successful leadership through the personal and professional choices of the most influential people in business.
More episodes and clips